EUVIMEDEUVIMED entdecken
Crossref

Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

Selin Cebeci, Emir Serraç, Tuğrul Elverdi, Ayşe Salihoğlu, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Ahmet Emre Eşkazan

Clinical Lymphoma Myeloma and Leukemia · 2026-05 · 26 (5) · e661-e668.e2

DOI: 10.1016/j.clml.2026.02.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-05. Verfasst von Selin Cebeci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Türki…. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes, Autoimmune Diseases, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Systemic inflammatory and autoimmune diseases (SIADs) are frequently reported in association with myeloid neoplasms; however, their prognostic relevance in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) remains unclear. This study aimed to evaluate the frequency of SIADs and their impact on survival outcomes in patients with MDS and CMML. MATERIALS AND METHODS We retrospectively analyzed patients diagnosed with MDS, CMML, or acute myeloid leukemia transformed from MDS between 2000 and 2020. Medical records were reviewed for the presence of SIADs, demographic and laboratory characteristics, bone marrow findings, cytogenetics, treatments, and responses. Overall survival (OS), progression-free survival (PFS), and leukemia-free survival (LFS) were assessed. RESULTS A total of 178 patients were included (mean age 66.5 years; 52.2% male). MDS was diagnosed in 75.3% of cases, most commonly refractory cytopenia with multilineage dysplasia, while 15% had CMML. SIADs were identified in 29.7% of patients, most frequently Hashimoto's thyroiditis, seronegative arthritis, Behçet syndrome, and panniculitis. Patients with SIADs were significantly younger than those without SIADs (P = .005). No significant differences were observed in gender, comorbidities, cytogenetic risk, or baseline laboratory parameters. Overall survival, progression-free survival, and leukemia-free survival were comparable between groups. Although SIADs were associated with a nonsignificant trend toward increased disease progression and leukemic transformation, high-risk disease scores were independently associated with inferior survival outcomes. CONCLUSION SIADs were common in patients with MDS and CMML but did not significantly affect survival outcomes, supporting previous reports that SIADs may not independently influence prognosis in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesAutoimmune DiseasesInflammationHumansFemaleMaleAgedRetrospective StudiesMiddle AgedPrognosisAged, 80 and overAdult

Stichwörter der Autor:innen

AutoimmunityInflammationLeukemic transformationSurvivalTrisomy 8

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Türkiye.
  • Department of Emergency Medicine, University of Health Sciences, Prof. Dr. Cemil Taşcıoğlu City Hospital, Şişli, Istanbul, Türkiye.
  • Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Türkiye.
  • Department of Hematology, University of Health Sciences, Istanbul Başakşehir Çam and Sakura City Hospital, Başakşehir, Istanbul, Türkiye.
  • Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Türkiye. Electronic address: emre.eskazan@iuc.edu.tr.

Zitieren

APA

Cebeci, S., Serraç, E., Elverdi, T., Salihoğlu, A., Ar, M. C., Öngören, Ş., Başlar, Z., & Eşkazan, A. E. (2026). Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia, 26(5), e661-e668.e2. https://doi.org/10.1016/j.clml.2026.02.011

Vancouver

Cebeci S, Serraç E, Elverdi T, Salihoğlu A, Ar MC, Öngören Ş, et al. Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2026;26(5):e661-e668.e2. doi:10.1016/j.clml.2026.02.011

BibTeX
@article{Cebeci2026,
  author = {Cebeci, Selin and Serraç, Emir and Elverdi, Tuğrul and Salihoğlu, Ayşe and Ar, Muhlis Cem and Öngören, Şeniz and Başlar, Zafer and Eşkazan, Ahmet Emre},
  title = {Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {5},
  pages = {e661--e668.e2},
  doi = {10.1016/j.clml.2026.02.011}
}
Kostenlos starten →